Here are eight key developments from spine and orthopedic devicemakers since Oct. 9. 1. Johnson & Johnson MedTech began the ...

On Tuesday, Johnson & Johnson (NYSE:JNJ) reported a third-quarter adjusted EPS of $2.42, down 9.0% year-over-year, beating ...

Q3 2024 Earnings Call Transcript October 15, 2024 Johnson & Johnson beats earnings expectations. Reported EPS is $2.42, ...

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), retaining the price ...

Matt Miksic, an analyst from Barclays, maintained the Hold rating on Johnson & Johnson (JNJ – Research Report). The associated price ...

TORONTO—While the FDA has already doled out green lights to about 950 medical devices backed by artificial intelligence or ...

Johnson & Johnson’s medtech acquisitions over the past year have fueled growth for its cardiovascular group, offsetting challenges in businesses like orthopedics and surgery.

Sales of Johnson & Johnson’s oncology drugs jumped nearly 19% in the third quarter, driven by cancer treatment Darzalex which ...

Despite the topline growth, J&J’s net earnings fell 37.5% to $2.6 billion, down from $4.3 billion in Q3 2023. Johnson & ...

Johnson & Johnson raised its 2024 profit and sales forecasts on Tuesday after reporting strong sales of oncology drugs and ...

The innovative medicine and medtech segments showed solid sales growth. Johnson & Johnson reported a strong increase in sales, but earnings fell due to one-time charges. In the wake of last year's ...

Johnson & Johnson shares rose 0.7% in premarket trades Tuesday after the drugmaker reported better-than-expected ...